RecruitingPhase 3NCT06900920
A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Intervention
- TQB3473 Tablets(drug)
- Enrollment
- 199 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2025 – 2027
Study locations (30)
- The first affiliated hospital of ustc anhui provincial hospital, Hefei, Anhui, China
- The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
- Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing Municipality, China
- Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
- The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
- The First Hospital of Lanzhou University, Lanzhou, Gansu, China
- Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
- Shenzhen Nanshan People's Hospital, Shenzhen, Guangdong, China
- Central People's Hospital of Zhanjiang, Zhanjiang, Guangdong, China
- The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
- The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
- The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China
- Affiliated Hospital of Hebei University / School of Clinical Medicine, Baoding, Hebei, China
- Affiliated Hospital of ChengDe Medical University, Chengde, Hebei, China
- The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06900920 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation